Holoclar 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
T/0060 
Transfer of Marketing Authorisation 
25/09/2023 
18/10/2023 
SmPC, 
Labelling and 
PL 
PSUSA/10352
Periodic Safety Update EU Single assessment - ex 
28/09/2023 
n/a 
PRAC Recommendation - maintenance 
/202302 
vivo expanded autologous human corneal epithelial 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
cells containing stem cells 
IAIN/0059/G 
This was an application for a group of variations. 
22/09/2023 
18/10/2023 
Annex II and 
PL 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.5.a - Administrative change - Change in the name 
and/or address of a manufacturer/importer 
responsible for batch release 
IAIN/0057 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
22/06/2023 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
IA/0054 
B.I.b.1.d - Change in the specification parameters 
20/04/2023 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
IAIN/0055 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
17/04/2023 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
Page 2/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0053 
B.I.b.z - Change in control of the AS - Other 
30/03/2023 
n/a 
variation 
PSUSA/10352
Periodic Safety Update EU Single assessment - ex 
16/03/2023 
n/a 
PRAC Recommendation - maintenance 
/202208 
vivo expanded autologous human corneal epithelial 
cells containing stem cells 
IAIN/0052 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
08/03/2023 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
IAIN/0051 
B.II.b.1.a - Replacement or addition of a 
20/02/2023 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IA/0050 
B.III.1.b.3 - Submission of a new/updated or 
06/02/2023 
n/a 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
R/0048 
Renewal of the marketing authorisation. 
10/11/2022 
13/01/2023 
The CHMP, having reviewed the available information on 
the status of the fulfilment of Specific Obligations and 
having confirmed the positive benefit risk balance, is of the 
opinion that the quality, safety and efficacy of this 
medicinal product continue to be adequately and 
sufficiently demonstrated and therefore recommends the 
renewal of the conditional MA for Holoclar, subject to the 
Specific Obligations and Conditions as laid down in Annex II 
to the opinion. 
Page 3/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10352
Periodic Safety Update EU Single assessment - ex 
29/09/2022 
n/a 
PRAC Recommendation - maintenance 
/202202 
vivo expanded autologous human corneal epithelial 
cells containing stem cells 
IB/0045 
B.III.1.b.2 - Submission of a new/updated or 
29/07/2022 
n/a 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
IAIN/0047 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
15/07/2022 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
IAIN/0046 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
23/06/2022 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
IB/0044 
B.I.z - Quality change - Active substance - Other 
01/06/2022 
n/a 
variation 
IA/0042/G 
This was an application for a group of variations. 
25/04/2022 
n/a 
B.III.1.b.3 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
Page 4/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.III.1.b.3 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
IAIN/0041/G 
This was an application for a group of variations. 
19/04/2022 
n/a 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
PSUSA/10352
Periodic Safety Update EU Single assessment - ex 
10/03/2022 
n/a 
PRAC Recommendation - maintenance 
/202108 
vivo expanded autologous human corneal epithelial 
cells containing stem cells 
Page 5/14 
 
 
 
 
 
 
 
 
 
 
 
R/0039 
Renewal of the marketing authorisation. 
14/10/2021 
09/12/2021 
The CHMP, having reviewed the available information on 
the status of the fulfilment of Specific Obligations and 
having confirmed the positive benefit risk balance, is of the 
opinion that the quality, safety and efficacy of this 
medicinal product continue to be adequately and 
sufficiently demonstrated and therefore recommends the 
renewal of the conditional MA for Holoclar, subject to the 
Specific Obligations and Conditions as laid down in Annex II 
to the opinion. 
PSUSA/10352
Periodic Safety Update EU Single assessment - ex 
30/09/2021 
n/a 
PRAC Recommendation - maintenance 
/202102 
vivo expanded autologous human corneal epithelial 
cells containing stem cells 
IB/0038 
B.I.b.z - Change in control of the AS - Other 
16/09/2021 
n/a 
variation 
IB/0036 
B.II.c.z - Change in control of excipients in the 
04/05/2021 
n/a 
Finished Product - Other variation 
PSUSA/10352
Periodic Safety Update EU Single assessment - ex 
11/03/2021 
n/a 
PRAC Recommendation - maintenance 
/202008 
vivo expanded autologous human corneal epithelial 
cells containing stem cells 
IB/0035 
B.II.d.2.a - Change in test procedure for the finished 
15/01/2021 
n/a 
product - Minor changes to an approved test 
procedure 
IB/0034 
B.I.b.2.a - Change in test procedure for AS or 
15/01/2021 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
Page 6/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
R/0032 
Renewal of the marketing authorisation. 
15/10/2020 
07/01/2021 
SmPC, Annex 
The CHMP, having reviewed the available information on 
II, Labelling 
the status of the fulfilment of Specific Obligations and 
and PL 
having confirmed the positive benefit risk balance, is of the 
opinion that the quality, safety and efficacy of this 
medicinal product continue to be adequately and 
sufficiently demonstrated and therefore recommends the 
renewal of the conditional MA for Holoclar, subject to the 
Specific Obligations and Conditions as laid down in Annex II 
to the opinion. 
PSUSA/10352
Periodic Safety Update EU Single assessment - ex 
01/10/2020 
n/a 
PRAC Recommendation - maintenance 
/202002 
vivo expanded autologous human corneal epithelial 
cells containing stem cells 
T/0031 
Transfer of Marketing Authorisation 
18/05/2020 
12/06/2020 
SmPC, Annex 
II, Labelling 
and PL 
IB/0029 
B.I.a.2.a - Changes in the manufacturing process of 
30/03/2020 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
PSUSA/10352
Periodic Safety Update EU Single assessment - ex 
12/03/2020 
n/a 
PRAC Recommendation - maintenance 
/201908 
vivo expanded autologous human corneal epithelial 
cells containing stem cells 
R/0026 
Renewal of the marketing authorisation. 
14/11/2019 
21/02/2020 
SmPC and 
Annex II 
IA/0027 
B.III.1.b.3 - Submission of a new/updated or 
04/10/2019 
n/a 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
Page 7/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturer 
PSUSA/10352
Periodic Safety Update EU Single assessment - ex 
05/09/2019 
n/a 
PRAC Recommendation - maintenance 
/201902 
vivo expanded autologous human corneal epithelial 
cells containing stem cells 
IB/0023 
B.I.a.1.k - Change in the manufacturer of AS or of a 
28/03/2019 
n/a 
starting material/reagent/intermediate for AS - New 
storage site of MCB and/or WCB 
PSUSA/10352
Periodic Safety Update EU Single assessment - ex 
14/03/2019 
n/a 
PRAC Recommendation - maintenance 
/201808 
vivo expanded autologous human corneal epithelial 
cells containing stem cells 
N/0024 
Minor change in labelling or package leaflet not 
22/02/2019 
21/02/2020 
PL 
connected with the SPC (Art. 61.3 Notification) 
R/0021 
Renewal of the marketing authorisation. 
15/11/2018 
15/01/2019 
SmPC 
The CHMP having reviewed the available information on the 
status of the fulfilment of Specific Obligations and having 
confirmed the positive benefit risk balance, is of the opinion 
that the quality, safety and efficacy of this medicinal 
product continue to be adequately and sufficiently 
demonstrated and therefore recommends the renewal of 
the conditional MA for Holoclar, subject to the Specific 
Obligations and Conditions as laid down in Annex II to the 
opinion. 
PSUSA/10352
Periodic Safety Update EU Single assessment - ex 
06/09/2018 
n/a 
PRAC Recommendation - maintenance 
/201802 
vivo expanded autologous human corneal epithelial 
cells containing stem cells 
Page 8/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0019 
B.I.b.2.e - Change in test procedure for AS or 
18/05/2018 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IB/0018/G 
This was an application for a group of variations. 
18/05/2018 
n/a 
B.I.z - Quality change - Active substance - Other 
variation 
B.I.z - Quality change - Active substance - Other 
variation 
PSUSA/10352
Periodic Safety Update EU Single assessment - ex 
08/03/2018 
n/a 
PRAC Recommendation - maintenance 
/201708 
vivo expanded autologous human corneal epithelial 
cells containing stem cells 
IB/0017 
B.I.z - Quality change - Active substance - Other 
04/01/2018 
n/a 
variation 
R/0015 
Renewal of the marketing authorisation. 
12/10/2017 
11/12/2017 
The CAT, having reviewed the available information on the 
status of the fulfilment of Specific Obligations and having 
confirmed the positive benefit risk balance, is of the opinion 
that the quality, safety and efficacy of this medicinal 
product continue to be adequately and sufficiently 
demonstrated and therefore recommends the renewal of 
the conditional MA for Holoclar, subject to the Specific 
Obligations and Conditions as laid down in Annex II to the 
Opinion. 
PSUSA/10352
Periodic Safety Update EU Single assessment - ex 
28/09/2017 
n/a 
PRAC Recommendation - maintenance 
/201702 
vivo expanded autologous human corneal epithelial 
Page 9/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
cells containing stem cells 
IA/0014/G 
This was an application for a group of variations. 
28/07/2017 
n/a 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.b.2.b - Change in test procedure for AS or 
starting material/reagent/intermediate - Deletion of 
a test procedure for the AS or a starting 
material/reagent/intermediate, if an alternative test 
procedure is already authorised 
B.II.e.7.b - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
B.II.e.7.b - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
B.III.2.a.2 - Change of specification(s) of a former 
non EU Pharmacopoeial substance to fully comply 
with the Ph. Eur. or with a national pharmacopoeia of 
a Member State - Excipient/AS starting material 
II/0012/G 
This was an application for a group of variations. 
22/06/2017 
11/12/2017 
SmPC and PL 
Page 10/14 
 
 
 
 
 
 
 
 
 
 
 
B.I.b.1.f - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Change outside the 
approved specifications limits range for the AS 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
PSUSA/10352
Periodic Safety Update EU Single assessment - ex 
09/03/2017 
n/a 
PRAC Recommendation - maintenance 
/201608 
vivo expanded autologous human corneal epithelial 
cells containing stem cells 
IB/0011 
B.I.b.2.e - Change in test procedure for AS or 
07/02/2017 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
R/0008 
Renewal of the marketing authorisation. 
13/10/2016 
08/12/2016 
The CHMP, having reviewed the available information on 
the status of the fulfilment of Specific Obligation and having 
confirmed the positive benefit risk balance, is of the opinion 
that the quality, safety and efficacy of this medicinal 
product continue to be adequately and sufficiently 
Page 11/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
demonstrated and therefore recommends the renewal of 
the conditional MA for Holoclar, subject to the Specific 
Obligation and Conditions as laid down in Annex II to the 
Opinion. 
N/0010 
Update of the labelling to include the unique 
03/11/2016 
11/12/2017 
Labelling and 
identifier 2D barcode as per QRD template v.10 and 
PL 
update of the package leaflet with the revised 
contact details of the local representative for France. 
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/10352
Periodic Safety Update EU Single assessment - ex 
02/09/2016 
n/a 
PRAC Recommendation - maintenance 
/201602 
vivo expanded autologous human corneal epithelial 
cells containing stem cells 
IA/0007/G 
This was an application for a group of variations. 
23/06/2016 
n/a 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.3 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
IB/0006 
B.II.c.2.z - Change in test procedure for an excipient 
10/06/2016 
n/a 
- Other variation 
Page 12/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0005/G 
This was an application for a group of variations. 
27/05/2016 
n/a 
B.II.c.1.c - Change in the specification parameters 
and/or limits of an excipient - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.3 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
PSUSA/10352
Periodic Safety Update EU Single assessment - ex 
17/03/2016 
n/a 
PRAC Recommendation - maintenance 
/201508 
vivo expanded autologous human corneal epithelial 
cells containing stem cells 
IB/0003 
B.II.z - Quality change - Finished product - Other 
18/12/2015 
n/a 
variation 
R/0001 
Renewal of the marketing authorisation. 
22/10/2015 
10/12/2015 
The CHMP, having reviewed the available information on 
the status of the fulfilment of Specific Obligations and 
having confirmed the positive benefit risk balance, is of the 
opinion that the quality, safety and efficacy of this 
medicinal product continue to be adequately and 
sufficiently demonstrated and therefore recommends the 
renewal of the conditional MA for Holoclar, subject to the 
Specific Obligations and Conditions as laid down in Annex II 
Page 13/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
to the Opinion. 
Page 14/14 
 
 
 
 
 
 
